scholarly journals Effectiveness of WhatsApp online group discussion for smoking relapse prevention: protocol for a pragmatic randomized controlled trial

Addiction ◽  
2020 ◽  
Vol 115 (9) ◽  
pp. 1777-1785
Author(s):  
Yee Tak Derek Cheung ◽  
Ching Han Helen Chan ◽  
Kin Sang Ho ◽  
Wai‐Yin Patrick Fok ◽  
Mike Conway ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Relapse Prevention ◽  
Controlled Trial ◽  
Group Discussion ◽  
Smoking Relapse ◽  
Pragmatic Randomized Controlled Trial ◽  
Randomized Controlled ◽  
Prevention Protocol ◽  
Online Group

scholarly journals Smoking relapse-prevention intervention for cancer patients: Study design and baseline data from the surviving SmokeFree randomized controlled trial

2016 ◽  
Vol 50 ◽  
pp. 84-89 ◽  
Author(s):  
Diana B. Díaz ◽  
Thomas H. Brandon ◽  
Steven K. Sutton ◽  
Lauren R. Meltzer ◽  
Hannah J. Hoehn ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Cancer Patients ◽  
Study Design ◽  
Relapse Prevention ◽  
Controlled Trial ◽  
Baseline Data ◽  
Smoking Relapse ◽  
Prevention Intervention ◽  
Randomized Controlled

scholarly journals Strategies to Avoid Returning to Smoking (STARTS): A randomized controlled trial of postpartum smoking relapse prevention interventions

2013 ◽  
Vol 36 (2) ◽  
pp. 565-573 ◽  
Author(s):  
Michele D. Levine ◽  
Marsha D. Marcus ◽  
Melissa A. Kalarchian ◽  
Yu Cheng
Keyword(s):  
Randomized Controlled Trial ◽  
Relapse Prevention ◽  
Controlled Trial ◽  
Smoking Relapse ◽  
Randomized Controlled ◽  
Prevention Interventions

scholarly journals Self-help materials for smoking relapse prevention: a process evaluation of the SHARPISH randomized controlled trial

2017 ◽  
Vol 40 (1) ◽  
pp. 98-105 ◽  
Author(s):  
Caitlin Notley ◽  
Annie Blyth ◽  
Vivienne Maskrey ◽  
Babu Karavadra ◽  
Tracey Brown ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Process Evaluation ◽  
Relapse Prevention ◽  
Controlled Trial ◽  
Smoking Relapse ◽  
Randomized Controlled ◽  
Self Help

scholarly journals Using WhatsApp and Facebook Online Social Groups for Smoking Relapse Prevention for Recent Quitters: A Pilot Pragmatic Cluster Randomized Controlled Trial

2015 ◽  
Vol 17 (10) ◽  
pp. e238 ◽  
Author(s):  
Yee Tak Derek Cheung ◽  
Ching Han Helen Chan ◽  
Chi-Keung Jonah Lai ◽  
Wai Fung Vivian Chan ◽  
Man Ping Wang ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Relapse Prevention ◽  
Controlled Trial ◽  
Social Groups ◽  
Cluster Randomized Controlled Trial ◽  
Smoking Relapse ◽  
Randomized Controlled ◽  
Cluster Randomized

scholarly journals Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial

2014 ◽  
Vol 1 (1) ◽  
Author(s):  
L. Mupfumi ◽  
B. Makamure ◽  
M. Chirehwa ◽  
T. Sagonda ◽  
S. Zinyowera ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Limited Resource ◽  
Hiv Treatment ◽  
Treatment Programs ◽  
Sputum Smear ◽  
Smear Microscopy ◽  
Pragmatic Randomized Controlled Trial ◽  
Randomized Controlled ◽  
Art Initiation

Abstract Introduction.  GeneXpert® MTB/RIF (Xpert) is now widely distributed in high human immunodeficiency virus (HIV)/tuberculosis (TB)-burden countries. Yet, whether the test improves patient-important outcomes within HIV treatment programs in limited resource settings is unknown. Methods.  To investigate whether use of Xpert for TB screening prior to initiation of antiretroviral treatment (ART) improves patient-important outcomes, in a pragmatic randomized controlled trial we assigned 424 patients to Xpert or fluorescence sputum smear microscopy (FM) at ART initiation. The primary endpoint was a composite of 3-month mortality and ART-associated TB. Results.  There was no difference in overall TB diagnosis at ART initiation (20% [n = 43] Xpert vs 21% [n = 45] FM; P = .80), with most patients in both groups treated empirically. There was no difference in time to TB treatment initiation {5 days (interquartile range [IQR], 3–13) vs 8 days [IQR, 3–23; P = .26]} or loss to follow-up (32 [15%] vs 38 [18%]; P = 0.38). Although a nonsignificant reduction in mortality occurred in the Xpert group (11 [6%] vs 17 [10%]; 95% CI, −9% to 2%; P = .19), there was no difference in the composite outcome (9% [n = 17] Xpert vs 12% [n = 21] FM; difference −3%; 95% CI, −9% to 4%). Conclusions.  Among HIV-infected initiating ART, centralized TB screening with Xpert did not reduce the rate of ART-associated TB and mortality, compared with fluorescence microscopy.

Sign in / Sign up

Export Citation Format

Share Document